Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
NBTX | US
0
0%
Healthcare
Biotechnology
31/03/2024
04/10/2024
5.19
5.12
5.38
5.09
Nanobiotix S.A. a clinical-stage biotechnology focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3 a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma head and neck cancers liver cancers prostate cancer pancreatic cancer esophageal cancer rectal cancer and non-small cell lung cancer. Nanobiotix S.A. has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China South Korea Singapore and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris France.
View LessLow Debt to Equity (< 0.25)
Strong Revenue Growth (> 10%)
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Rich in Valuation (Price to Book > 8)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
79.2%1 month
63.8%3 months
65.1%6 months
74.0%-
48.31
65.02
-27.42
0.54
-2.45
5.64
-
-22.30M
246.03M
246.03M
-
-253.32
-
182.10
-198.69
4.84
0.10
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
1.18
Range1M
1.18
Range3M
1.46
Rel. volume
1.06
Price X volume
71.10K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Vanda Pharmaceuticals Inc | VNDA | Biotechnology | 4.63 | 269.88M | 0.87% | n/a | 1.55% |
Genfit SA | GNFT | Biotechnology | 5.3861 | 268.80M | 4.67% | 13.90 | 104.08% |
Compass Therapeutics Inc. Common Stock | CMPX | Biotechnology | 1.93 | 265.55M | 0.52% | n/a | 0.00% |
Progenitor Inc | PGEN | Biotechnology | 0.9 | 263.38M | -6.82% | n/a | 14.69% |
Mersana Therapeutics Inc | MRSN | Biotechnology | 2.12 | 260.07M | 3.92% | n/a | 383.37% |
ChromaDex Corporation | CDXC | Biotechnology | 3.38 | 256.65M | -2.59% | n/a | 10.17% |
Poseida Therapeutics Inc | PSTX | Biotechnology | 2.61 | 253.52M | -1.14% | n/a | 137.55% |
Fulcrum Therapeutics Inc | FULC | Biotechnology | 3.82 | 252.91M | -1.29% | n/a | 3.53% |
Amarin Corporation plc | AMRN | Biotechnology | 0.6058 | 249.09M | 0.30% | n/a | 1.47% |
2seventy bio Inc | TSVT | Biotechnology | 4.81 | 247.70M | 0.00% | n/a | 107.07% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
CPI Card Group Inc | PMTS | Building Products & Equipment | 23.62 | 261.38M | 4.61% | 17.90 | -621.78% |
Virco Mfg. Corporation | VIRC | Building Products & Equipment | 13.5 | 219.91M | 1.89% | 8.52 | 39.79% |
Kewaunee Scientific Corporation | KEQU | Building Products & Equipment | 31.64 | 90.86M | -0.32% | 5.47 | 19.82% |
Saga Communications Inc | SGA | Broadcasting - Radio | 14 | 87.66M | -1.27% | 14.62 | 7.10% |
REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 7.64 | 83.40M | -1.93% | n/a | 58.43% |
Urban One Inc | UONEK | Broadcasting - Radio | 1.02 | 57.65M | -4.67% | n/a | 268.43% |
Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 12.89 | 19.79M | -2.50% | n/a | 204.46% |
ILAG | ILAG | Building Products & Equipment | 1.0599 | 19.14M | -0.93% | n/a | 5.48% |
Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 0.695 | 8.47M | -4.15% | n/a | 16.03% |
Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.6199 | 5.90M | 6.82% | n/a | 19.98% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -2.45 | 0.76 | Cheaper |
Ent. to Revenue | 5.64 | 3,674.48 | Cheaper |
PE Ratio | - | 38.01 | - |
Price to Book | 65.02 | 14.10 | Expensive |
Dividend Yield | - | 2.22 | - |
Std. Deviation (3M) | 65.06 | 74.67 | Par |
Debt to Equity | -27.42 | -1.82 | Cheaper |
Debt to Assets | 0.54 | 0.26 | Expensive |
Market Cap | 246.03M | 3.73B | Emerging |